Valuation: ACADIA Pharmaceuticals Inc.

Market Cap 4.49B 3.94B 3.63B 3.36B 6.36B 430B 6.49B 43.67B 16.97B 210B 16.85B 16.48B 730B P/E 2026 *
68.2x
P/E 2027 * 35.6x
Enterprise Value 3.52B 3.09B 2.85B 2.64B 5B 337B 5.1B 34.28B 13.32B 165B 13.23B 12.94B 573B EV / Sales 2026 *
2.84x
EV / Sales 2027 * 2.37x
Free-Float
99.68%
Yield 2026 *
-
Yield 2027 * -
1 day-1.51%
1 week+2.14%
Current month+1.74%
1 month+18.62%
3 months+14.10%
6 months-4.35%
Current year-3.63%
1 week 25.13
Extreme 25.13
26.35
1 month 20.84
Extreme 20.84
27.31
Current year 19.89
Extreme 19.89
27.81
1 year 19.69
Extreme 19.69
28.35
3 years 13.4
Extreme 13.4
33.99
5 years 12.24
Extreme 12.24
33.99
10 years 12.24
Extreme 12.24
58.72
Manager TitleAgeSince
Chief Executive Officer 55 20/09/2024
Director of Finance/CFO 52 10/09/2021
Chief Tech/Sci/R&D Officer - 04/08/2025
Director TitleAgeSince
Director/Board Member 68 01/05/2008
Chairman 55 10/06/2016
Director/Board Member 73 25/11/2015
Date Insider Type Main position Quantity % Market Cap.
06-26Sell

Controller/Auditor

-11,421 0.0067%
05-29
Baker Bros. Advisors LP
FreeCompany 101,260 0.0591%
05-29Fiscal year

Director

41,529 0.0243%
Change 5-day change 1-year change 3-year change Capi.($)
-1.53%+2.14%+22.45%+3.92% 4.49B
-0.24%+1.85%+3.13%+8.40% 49.74B
-0.92%+0.76%+418.47%+594.34% 40.49B
-2.91%+3.14%+22.67%+55.76% 34.35B
-2.29%+0.07%+23.64%-7.33% 34.75B
-0.79%+2.02%+3.83%+36.42% 26.98B
+2.89%+1.99% - - 16.58B
-3.07%-2.50%+64.34%+119.19% 15.6B
-2.64%+6.36%+103.74%+101.59% 14.27B
-2.70%-2.04%+12.37%+17.77% 13.76B
Average -1.54%+3.95%+74.96%+103.34% 25.1B
Weighted average by Cap. -1.56%+4.35%+91.96%+130.94%

Financials

2026 *2027 *
Net sales 1.24B 1.09B 1B 928M 1.76B 119B 1.8B 12.08B 4.69B 58.14B 4.66B 4.56B 202B 1.4B 1.22B 1.13B 1.04B 1.98B 134B 2.02B 13.58B 5.28B 65.38B 5.24B 5.12B 227B
Net income 65.75M 57.67M 53.24M 49.2M 93.26M 6.3B 95.12M 640M 249M 3.08B 247M 242M 10.7B 134M 117M 108M 100M 190M 12.81B 193M 1.3B 506M 6.27B 502M 491M 21.76B
Net Debt -965M -846M -781M -722M -1.37B -92.36B -1.4B -9.39B -3.65B -45.2B -3.62B -3.54B -157B -1.18B -1.03B -953M -881M -1.67B -113B -1.7B -11.46B -4.45B -55.16B -4.42B -4.32B -191B
Logo ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc.is a biopharmaceutical company. The Company is focused on innovation that makes the difference for underserved neurological and rare disease communities around the world. Its commercial portfolio includes the first and only FDA-approved treatments for Parkinson's disease psychosis and Rett syndrome. It is also developing therapeutic advancements with diverse pipelines that include mid- to late-stage programs in Alzheimer's disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. Its pipeline of product candidates includes Remlifanserin (formerly ACP-204), ACP-211, ACP-711, ACP-271, ACP-259, and Antisense Oligonucleotide (ASO) Program. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. DAYBUE (trofinetide) is developed for the treatment of Rett Syndrome.
Employees
797
Date Price Change Volume
08/07/26 $25.74 -1.76% 510,021
07/07/26 $26.20 +1.67% 1,674,460
06/07/26 $25.77 -0.77% 1,155,022
02/07/26 $25.97 +3.06% 1,586,395
01/07/26 $25.20 -0.40% 1,417,658
Trader
Investor
Global
Quality
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
26.20USD
Average target price
32.65USD
Spread / Average Target
+24.62%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ACAD Stock